4 Largecap 25 Per Cent Operating Margin Low Debt Promoter Backed Stocks to Watch for Future Multibagger Potential: TCS, Sun Pharma, HAL and Divi's Labs

25 per cent operating margin low debt promoter backed stocks to watch for multibagger potential start with a simple filter: size, a clean financial record and earnings that keep growing. TCS, Sun Pharma, HAL and Divi's Labs meet that test, with market caps from Rs 3.01 lakh crore to Rs 8.11 lakh crore and TCS offering the highest return on equity at 43.37%. Each of these companies has an operating margin of at least 25 per cent, a debt to equity ratio below 0.3 and a promoter holding of at least 50 per cent, a return on equity of at least 10 per cent and profit growth in FY26 and in the latest quarter, and net profit rose in FY26 and in the latest quarter.

This list covers companies with an operating margin of at least 25 per cent, a debt to equity ratio below 0.3 and a promoter holding of at least 50 per cent, a return on equity of at least 10 per cent and profit growth in FY26 and in the latest quarter, rising profit in FY26 and the latest quarter, market capitalisation above Rs 1,00,000 crore, and complete, verifiable financials, ranked by market capitalisation. Each company has a market cap above Rs 1 lakh crore. Investors screening 25 per cent operating margin low debt promoter backed stocks usually begin with size and balance sheet strength, and this list follows the same logic. All figures are as of 12 November 2026 and are drawn from NSE and BSE data and company filings.

Click Here – Get Free Investment Predictions

What Are 25 Per Cent Operating Margin Low Debt Promoter Backed Stocks and Why Do They Attract Multibagger Interest?

25 per cent operating margin low debt promoter backed stocks are shares of large companies that keep at least twenty five paise of operating profit from every rupee of sales, whose borrowing is small compared with shareholder funds and in which the promoters own at least half of the business. The four here cover IT services, pharmaceuticals, pharmaceutical ingredients and defence aerospace.

A rich margin shows pricing strength, low debt keeps the balance sheet safe, and a large promoter stake shows that the owners have their own wealth tied to the company. Within 25 per cent operating margin low debt promoter backed stocks, the four companies show rising profit. In 25 per cent operating margin low debt promoter backed stocks, each of the four also posted growth in the latest quarter. For 25 per cent operating margin low debt promoter backed stocks, both FY26 and the latest quarter showed growth. Whichever way you read 25 per cent operating margin low debt promoter backed stocks, the common thread is rising profit backed by complete financial data. Investors researching 25 per cent operating margin low debt promoter backed stocks get a fuller picture by reading growth and valuation together. The table below lines up 25 per cent operating margin low debt promoter backed stocks on size, growth and valuation, using complete FY26 and latest quarter numbers. Past performance does not guarantee future returns, so use 25 per cent operating margin low debt promoter backed stocks as a starting point for your own research.

25 Per Cent Operating Margin Low Debt Promoter Backed Stocks at a Glance: Price, Market Cap, PE and ROE

Prices are closing prices as of 12 November 2026. TCS combines the lowest PE of the group, 15.65, with the highest return on equity, 43.37%.

Stock	CMP (Rs)	Market Cap (Rs Cr)	PE	Industry PE	ROE	Debt to Equity	52-Week Range (Rs)
Tata Consultancy Services	2,442.40	8,11,455	15.65	18.27	43.37%	0.10	1,976.80 to 3,350.00
Sun Pharmaceutical Industries	1,885	4,52,944	37.38	36.42	13.74%	0.06	1,583.70 to 2,046.90
Hindustan Aeronautics	4,843.40	3,30,891	35.50	48.59	22.21%	0.00	3,479.10 to 5,149.90
Divi's Laboratories	11,485	3,00,829	102.85	36.42	15.32%	0.00	5,647.50 to 11,565.50

TCS: Return on Equity of 43.37%

TCS is India's largest IT services company by market capitalisation and runs large AI and data practices for global clients. It reported FY26 revenue of Rs 2,71,423 crore, up 4.68% year on year, and net profit of Rs 49,454 crore, up 1.35%. Net profit has compounded at 6.49% a year since FY22, while revenue has grown 8.51% a year. Operating margin was 27.07% in FY26. The debt-to-equity ratio is 0.10, which keeps interest costs low.

In the September 2026 quarter, revenue rose 11.79% to Rs 74,525 crore and net profit grew 14.86% to Rs 13,934 crore. Domestic institutions raised their holding from 12.01% in June 2025 to 13.47% in June 2026. The stock trades at a PE of 15.65 against an industry PE of 18.27, below the sector average, with a return on equity of 43.37%. The dividend yield is 4.91%.

Sun Pharma: 35.75% Profit CAGR Since FY22

Sun Pharmaceutical Industries is one of India's largest drugmakers and sells generic and specialty medicines in India and overseas. It reported FY26 revenue of Rs 61,673.94 crore, up 12.69% year on year, and net profit of Rs 11,564.52 crore, up 5.32%. Net profit has compounded at 35.75% a year since FY22, while revenue has grown 11.62% a year. Operating margin was 31.47% in FY26. The debt-to-equity ratio is 0.06, which keeps interest costs low.

The stock trades at a PE of 37.38 against an industry PE of 36.42, with a return on equity of 13.74%. In the June 2026 quarter, revenue rose 11.93% to Rs 16,023.50 crore and net profit grew 26.41% to Rs 2,910.80 crore. The share price has gained 111.23% over five years. Domestic institutions raised their holding from 20.23% in September 2025 to 22.27% in September 2026.

HAL: Return on Equity of 22.21%

Hindustan Aeronautics is India's state-owned aerospace company that designs, makes and services fighter jets, helicopters, engines and avionics. It reported FY26 revenue of Rs 36,787.95 crore, up 9.68% year on year, and net profit of Rs 9,115.52 crore, up 8.98%. Net profit has compounded at 15.74% a year since FY22, while revenue has grown 9.48% a year. Operating margin was 40.89% in FY26. The debt-to-equity ratio is 0.00, which keeps interest costs low.

In the June 2026 quarter, revenue rose 15.26% to Rs 6,415.41 crore and net profit grew 14.88% to Rs 1,589.66 crore. The share price has gained 624.91% over five years. Domestic institutions raised their holding from 8.71% in September 2025 to 12.56% in September 2026. The stock trades at a PE of 35.50 against an industry PE of 48.59, below the sector average, with a return on equity of 22.21%.

Divi's Labs: Debt-to-Equity of 0.00

Divi's Laboratories makes active pharmaceutical ingredients and intermediates and runs a large custom synthesis business for global drug companies. It reported FY26 revenue of Rs 11,067 crore, up 13.95% year on year, and net profit of Rs 2,568 crore, up 17.21%. Revenue has compounded at 5.09% a year since FY22. Operating margin was 36.70% in FY26. The debt-to-equity ratio is 0.00, which keeps interest costs low.

The stock trades at a PE of 102.85 against an industry PE of 36.42, with a return on equity of 15.32%. In the June 2026 quarter, revenue rose 24.32% to Rs 3,144 crore and net profit grew 65.50% to Rs 902 crore. The share price has gained 70.59% over five years and 38.07% over the past year. Foreign investors raised their holding from 19.39% in September 2025 to 20.38% in September 2026.

25 Per Cent Operating Margin Low Debt Promoter Backed Stocks: Financial Comparison on Growth and Margins

The table compares scale and growth across these 25 per cent operating margin low debt promoter backed stocks. Latest quarter means the most recent reported quarter for each company, and only metrics that are positive for every company are shown.

Stock	Revenue (Rs Cr)	Net Profit (Rs Cr)	Revenue Growth (YoY)	4-Year Revenue CAGR	Latest Quarter Revenue Growth	Operating Margin (Latest Quarter)
TCS	2,71,423	49,454	4.68%	8.51%	11.79%	27.53%
Sun Pharma	61,673.94	11,564.52	12.69%	11.62%	11.93%	32.52%
HAL	36,787.95	9,115.52	9.68%	9.48%	15.26%	44.22%
Divi's Labs	11,067	2,568	13.95%	5.09%	24.32%	42.82%

Check the Univest Screener for live data on these 25 per cent operating margin low debt promoter backed stocks

Institutional Holding in TCS, Sun Pharma, HAL and Divi's Labs

Institutional holding shows who is backing these 25 per cent operating margin low debt promoter backed stocks alongside the promoter. The table uses the latest reported quarter for each. Divi's Labs has the deepest institutional backing, with FII and DII together holding 39.55% as of September 2026. Domestic institutions increased their holding over the past year in TCS (from 12.01% to 13.47%), Sun Pharma (from 20.23% to 22.27%) and HAL (from 8.71% to 12.56%). Keeping an eye on the Nifty 100 alongside this list shows whether these shares are moving with the wider market.

Stock	Promoter	FII	DII	Public	Quarter
TCS	71.77%	9.06%	13.47%	5.70%	June 2026
Sun Pharma	52.68%	14.36%	22.27%	10.70%	September 2026
HAL	71.64%	9.42%	12.56%	6.38%	September 2026
Divi's Labs	51.88%	20.38%	19.17%	8.58%	September 2026

Risks to Weigh in 25 Per Cent Operating Margin Low Debt Promoter Backed Stocks

Being careful with 25 per cent operating margin low debt promoter backed stocks means looking at what can slow the story as well as what can speed it up. Four points matter most:

• Past growth may not repeat.
• Share prices can move sharply in either direction.
• Valuation: Divi's Labs trades at a PE of 102.85 against an industry PE of 36.42, so earnings need to keep growing to support the price.
• Concentration: Holding all 4 names puts the allocation in one sector, so size each position to match your risk appetite.

How to Choose Between 25 Per Cent Operating Margin Low Debt Promoter Backed Stocks

Picking from 25 per cent operating margin low debt promoter backed stocks comes down to four checks, applied in order.

1. Check balance sheet strength first, and prefer a debt-to-equity ratio below 1 for non-financial companies.
2. Compare each PE with the industry PE (18.27 to 48.59) and ask whether the growth rate justifies any gap.
3. Track net profit growth, the operating margin and the return on equity in every quarterly result.
4. Stagger entries across quarters and review institutional holding every reporting season.

Download the Univest iOS App or Univest Android App to track TCS, Sun Pharma, HAL and Divi's Labs live prices.

Conclusion

Among 25 per cent operating margin low debt promoter backed stocks, TCS stands out for the highest return on equity at 43.37%, Sun Pharma for the fastest profit growth, 35.75% a year since FY22, HAL for the biggest five-year price gain at 624.91% and Divi's Labs for the strongest latest-quarter profit growth at 65.50%. Which one suits a portfolio depends on how much valuation risk it can carry, so staggering entries and reviewing each quarterly result is a sound habit. Investors comparing 25 per cent operating margin low debt promoter backed stocks should rank them on growth, financial strength and the price paid, and anyone who wants personalised guidance can consult a SEBI-registered advisor before acting.

Frequently Asked Questions on 25 Per Cent Operating Margin Low Debt Promoter Backed Stocks to Watch

Which are the best 25 per cent operating margin low debt promoter backed stocks to watch for multibagger potential?

Ans. TCS, Sun Pharma, HAL and Divi's Labs are the 4 names this list highlights, with market caps of Rs 8,11,455 crore, Rs 4,52,944 crore, Rs 3,30,891 crore and Rs 3,00,829 crore respectively. TCS is notable for the highest return on equity at 43.37%. Sun Pharma stands out for the fastest profit growth, 35.75% a year since FY22. HAL offers the biggest five-year price gain at 624.91%. Divi's Labs brings the strongest latest-quarter profit growth at 65.50%. These are watchlist names for 25 per cent operating margin low debt promoter backed stocks, not recommendations, so match each one to your own risk profile and time horizon.

Is TCS a good stock for long-term investors?

Ans. TCS has a return on equity of 43.37%, a PE of 15.65 against an industry PE of 18.27 and a market cap of Rs 8,11,455 crore. Net profit has compounded at 6.49% a year since FY22, and FY26 revenue rose 4.68% while September 2026 quarter net profit grew 14.86%. Long-term returns in 25 per cent operating margin low debt promoter backed stocks depend on earnings growth and the price paid at entry, so staggering purchases and consulting a SEBI-registered advisor is sensible.

Can Sun Pharma become a multibagger from here?

Ans. Sun Pharma has already gained 111.23% in five years, so another multi-fold move would need sustained earnings growth. A multibagger outcome in 25 per cent operating margin low debt promoter backed stocks requires earnings to keep growing faster than the market for several years. Net profit has compounded at 35.75% a year since FY22, and FY26 revenue rose 12.69%. At a PE of 37.38 against an industry PE of 36.42, valuation should be checked against that growth before investing.

What is the market cap of TCS, Sun Pharma, HAL and Divi's Labs?

Ans. As of 12 November 2026, TCS has a market cap of Rs 8,11,455 crore, Sun Pharma has a market cap of Rs 4,52,944 crore, HAL has a market cap of Rs 3,30,891 crore and Divi's Labs has a market cap of Rs 3,00,829 crore. All of them qualify as largecaps. Market cap changes daily with the share price, so check the latest figure on the Univest Screener or on NSE before taking a decision on 25 per cent operating margin low debt promoter backed stocks.

What are the risks of investing in 25 per cent operating margin low debt promoter backed stocks?

Ans. The main risks are market swings, slower growth than expected and valuations that already reflect good news. Companies with strong balance sheets and steady earnings handle these better. Divi's Labs trades at a PE of 102.85 against an industry PE of 36.42, so earnings growth needs to hold up.

Why is Divi's Labs trading at a PE of 102.85?

Ans. Divi's Labs' PE of 102.85 compares with an industry PE of 36.42. The market is paying a premium for a return on equity of 15.32% and latest-quarter profit growth of 65.50%, which also means the stock is more sensitive if growth slows. Investors in 25 per cent operating margin low debt promoter backed stocks who are comfortable with higher valuation risk may prefer to stagger purchases instead of investing in one go.

How much do institutions hold in TCS, Sun Pharma, HAL and Divi's Labs?

Ans. As of the latest reported quarter, FII and DII together hold 22.53% of TCS (9.06% and 13.47%), 36.63% of Sun Pharma (14.36% and 22.27%), 21.98% of HAL (9.42% and 12.56%) and 39.55% of Divi's Labs (20.38% and 19.17%). Rising institutional holding is a useful signal in 25 per cent operating margin low debt promoter backed stocks, though it should be read with earnings trends rather than on its own.